ACT

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
13	多発性硬化症／視神経脊髄炎	609

13. 多発性硬化症／視神経脊髄炎

臨床試験数 : 3,340 / 薬物数 : 2,163 - (DrugBank : 383) / 標的遺伝子数 : 241 - 標的パスウェイ数 : 238

trials per page:

Showing 1 to 10 of 609 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2022-003170-23-FI (EUCTR)	20/12/2022	30/09/2022	Hydroxychloroquine in progressive MS	Prospective, randomized, double-blind, placebo-controlled, single-center comparative trial evaluatin ...	Progressive multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10053395;Term: Pro ...	Trade Name: Oxiklorin Product Name: Oxiklorin INN or Proposed INN: Hydroxychloroquine sulfate	Varsinais-Suomen sairaanhoitopiirin kuntayhtymä	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	30	Phase 2	Finland
2	NCT05532163 (ClinicalTrials.gov)	November 1, 2022	5/9/2022	A Study to Investigate the Radiological Onset of Action After Treatment Initiation With Subcutaneous ...	A Prospective, Multicenter, Interventional, Open-Label, Single-arm Phase IV Study Over 24 Weeks to I ...	Multiple Sclerosis, Relapsing-Remitting	Drug: Natalizumab	Biogen	NULL	Not yet recruiting	18 Years	60 Years	All	40	Phase 4	NULL
3	EUCTR2018-001896-19-DE (EUCTR)	06/07/2022	05/04/2022	Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU- ...	Randomized, double-blind, placebo-controlled, multicenter Phase 2 trial assessing the effect of IMU- ...	relapsing-remitting multiple sclerosis MedDRA version: 21.1;Level: PT;Classification code 10063399;T ...	Product Name: VIDOFLUDIMUS CALCIUM Product Code: IMU-838-RC INN or Proposed INN: Vidofludimus calcium	Immunic AG	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	270	Phase 2	Poland;Ukraine;Romania;Bulgaria;Germany
4	NCT05441488 (ClinicalTrials.gov)	June 28, 2022	28/6/2022	Masitinib in the Treatment of Patients With Primary Progressive or Non-active Secondary Progressive ...	A 96-Week, Prospective, Multicenter, Randomised, Double-Blind, Placebo-Controlled, Phase 3 Study to ...	Progressive Multiple Sclerosis	Drug: Placebo;Drug: Masitinib (4.5)	AB Science	NULL	Recruiting	18 Years	65 Years	All	800	Phase 3	France;Greece;Italy;Poland;Russian Federation;Spain;Sweden;Ukraine
5	EUCTR2021-003296-33-GR (EUCTR)	17/06/2022	28/12/2021	OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMAB ON LEPTOMENINGEAL INFLAMMATION I ...	OPEN-LABEL MULTICENTER STUDY TO DETERMINE THE EFFECT OF OCRELIZUMAB ON LEPTOMENINGEAL INFLAMMATION I ...	Active progressive multiple sclerosis MedDRA version: 20.0;Level: HLT;Classification code 10052785;T ...	Trade Name: OCREVUS Product Name: OCRELIZUMAB Product Code: RO4964913 INN or Proposed INN: Ocrelizumab O ...	F. Hoffmann-La Roche Ltd.	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 4	Greece;Russian Federation
6	EUCTR2021-005746-15-ES (EUCTR)	09/05/2022	10/05/2022	A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients with Multi ...	A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety An ...	Primary Progressive Multiple Sclerosis (PPMS)Relapsing Multiple Sclerosis (RMS) MedDRA version: 21.1 ...	Trade Name: Ocrevus Product Name: ocrelizumab 300mg/10ml Product Code: RO4964913/F07 INN or Proposed IN ...	Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La R ...	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	1300	Phase 3	Serbia;Portugal;Belarus;United States;Estonia;Slovakia;Greece;Spain;Ukraine;Russian Federation;Israe ...
7	NCT05232825 (ClinicalTrials.gov)	May 3, 2022	27/1/2022	A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investiga ...	A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical ...	Relapsing Multiple Sclerosis;Primary Progressive Multiple Sclerosis	Drug: Ocrelizumab IV;Drug: Ocrelizumab SC;Drug: Methylprednisolone IV;Drug: Diphenhydramine IV;Drug: ...	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	65 Years	All	234	Phase 3	United States;Australia;Brazil;Czechia;Italy;New Zealand;Poland;Spain;Turkey;Canada;Russian Federati ...
8	NCT05090371 (ClinicalTrials.gov)	March 2, 2022	12/10/2021	A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (Nf ...	A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerab ...	Relapsing-Remitting Multiple Sclerosis	Drug: Ofatumumab;Drug: Disease modifying treatment (DMT)	Novartis Pharmaceuticals	NULL	Recruiting	18 Years	50 Years	All	150	Phase 4	United States;Canada
9	NCT05119569 (ClinicalTrials.gov)	March 1, 2022	29/10/2021	A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)	A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of Fenebrutinib in ...	Relapsing Multiple Sclerosis	Drug: Fenebrutinib;Drug: Placebo	Hoffmann-La Roche	NULL	Active, not recruiting	18 Years	55 Years	All	109	Phase 2	United States;Bosnia and Herzegovina;Croatia;Czechia;Serbia;Slovakia
10	NCT05423769 (ClinicalTrials.gov)	January 19, 2022	14/6/2022	Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remit ...	Safety and Effectiveness of Generic Fingolimod (Sphingomod®, Hikma) in Patients With Relapsing-Remit ...	Relapsing-Remitting Multiple Sclerosis	Drug: Fingolimod	Hikma Pharmaceuticals LLC	NULL	Active, not recruiting	18 Years	N/A	All	30		Egypt

First Previous1 2 3 4 5…61Next Last